China Levofloxacin Investigation Market Report 2018-2022

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
28
China Levofloxacin Investigation Market Report 2018-2022

Dublin, Jan. 22, 2019 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Levofloxacin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The antibacterial drug segment is the largest and most profitable segment of the global pharmaceuticals market. As antibacterial drugs that develop rapidly in recent years, quinolones are receiving more and more attention from all over the world. As a laevo isomer of Ofloxacin, Levofloxacin has the same antibacterial spectrum, double antibacterial effect, and lower toxicity. Currently, fluoroquinolones are second only to cephalosporins and penicillins on the antibacterial market. Levofloxacin, a third-generation fluoroquinolone, was developed by Daiichi Pharmaceutical Co., Ltd. (merged with Sankyo Co., Ltd. into "Daiichi Sankyo" in 2005) and first marketed in Japan in 1994.

In 1995, Levofloxacin APIs and tablets manufactured by Daiichi Pharmaceutical Co., Ltd. were admitted to the Chinese market. After that, Daiichi Pharmaceutical Co., Ltd. established its Chinese subsidiary Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. with an investment of USD 50 million. The subsidiary produces Levofloxacin preparations in China with the APIs from its parent company. The Levofloxacin tablets produced in China were launched in 1996 under the trade name Cravit. At that time, the retail price was about 7 CNY/tablet. Effective and inexpensive, Cravit saw its sales value rising on the Chinese market. Later, some Chinese companies developed generic Levofloxacin, and extended the dosage forms from tablets to injections, capsules, gels, etc.

According to market research, in 1998 when it had been launched in China for over one year, Levofloxacin became one of the top 100 drugs by sales value, and then showed an upward trend. The sales value of Levofloxacin declined from 2016 to 2017 after it reached CNY 1.23 billion in 2015. In 2017, China's Levofloxacin market was dominated by Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd., Yangtze River Pharmaceutical (Group) Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., and Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory. By sales value, Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. captured a market share of 29.1%. The injections, tablets, and eye drops accounted for about 63%, 20% and 13.7% respectively of China's Levofloxacin market. The other dosage forms had a small market share.

As environmental pollution and population aging intensify in China, there will be higher incidences of the main indications for Levofloxacin, for example, respiratory infection, urinary infection and intestinal infection. It is expected that China's Levofloxacin market will still have some growth potential from 2018 to 2022.

Topics Covered:

  • Development environment of Levofloxacin in China
  • Market size of Levofloxacin in China
  • Competitive landscape of China's Levofloxacin market
  • Prices of Levofloxacin in China
  • Prospect of China's Levofloxacin market from 2018 to 2022

Key Topics Covered:

1 Relevant Concepts of Levofloxacin 1.1 Indications for Levofloxacin 1.2 Development of Levofloxacin in China 1.3 Governmental Approval of Levofloxacin in China 2 Sales of Levofloxacin in China, 2013-2017 2.1 Sales Value of Levofloxacin 2.1.1 Overall Sales Value 2.1.2 Sales Value by Region 2.2 Sales Volume of Levofloxacin 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Region 2.3 Sales of Levofloxacin by Dosage Form in China, 2013-2017 2.3.1 Tablets 2.3.2 Capsules 2.3.3 Injections 2.3.4 Eye Drops 2.3.5 Ear Drops 2.3.6 Gels 3 Analysis On Major Levofloxacin Manufacturers in China, 2013-2017 3.1 Analysis on Market Share of Major Levofloxacin Manufacturers 3.1.1 Market Share by Sales Value 3.1.2 Market Share by Sales Volume 3.2 Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd.'s Levofloxacin in China 3.3 Yangtze River Pharmaceutical (Group) Co., Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Yangtze River Pharmaceutical (Group) Co., Ltd.'s Levofloxacin in China 3.4 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory 3.5 Santen Pharmaceutical Co., Ltd. 3.6 China Resources Double-Crane Pharmaceutical Co., Ltd. 4 Prices of Levofloxacin in China, 2017-2018 4.1 Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (Cravit) 4.2 Yangtze River Pharmaceutical (Group) Co., Ltd. (Zuoke) 4.3 Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (Lailixin) 4.4 Santen (Cravit) 4.5 China Resources Double-Crane Pharmaceutical Co., Ltd. (Lifuxing) 5 Prospects of China's Levofloxacin Market, 2018-2022 5.1 Analysis on Factors Influencing China's Levofloxacin Market 5.1.1 Favorable Factors 5.1.2 Unfavorable Factors 5.1 Forecast on Market Size 5.2 Forecast on Market Trend

Companies Mentioned

  • China Resources Double-Crane Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (Cravit)
  • Santen Pharmaceutical Co., Ltd.
  • Xinchang Pharmaceutical Factory
  • Yangtze River Pharmaceutical (Group) Co., Ltd. (Zuoke)
  • Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (Lailixin)

For more information about this report visit https://www.researchandmarkets.com/research/r...china?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Respiratory Drugs, Infectious Diseases Drugs, Antibiotics, Urological Disorders Drugs, Bronchitis Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

QuickFi Nabs Top Finovate Award for Fourth Time

Updated Category News Views 5

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Continue Reading
Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 3

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 5

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
Melissa Rivers Brings Her Wit Back to Emmys Carpet

Updated Category News Views 11

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Continue Reading
Sustainability Investments: $17 Trillion Wager Faces Divergence

Updated Category News Views 4

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Continue Reading
High-Grade Copper Spurs Optimism for PolarX in Alaska

Updated Category News Views 4

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

Continue Reading
Fermi's Founder Pushes for Board Overhaul: What's Next?

Updated Category News Views 4

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Continue Reading
Oil Markets Shift Focus: Pipelines Trump Drilling

Updated Category News Views 7

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Continue Reading
2026 Buy-Side Index Reveals State Market Variance

Updated Category News Views 6

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

Continue Reading
DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 14

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading

Top 5 Most Recently Viewed Articles

Six Flags Entertainment Achieves Cost Savings Amid Earnings Dip

Updated Category News Views 164

Financial Results of Six Flags Entertainment Six Flags Entertainment Corporation (NYSE: FUN) shares are showing a modest increase in trading. Recent financial reports for the combined entity of Six Flags and Cedar Fair illustrate a clear picture of the company's ongoing adjustments and strategies. Earnings Report Overview For the fourth quarter, Six Flags reported sales...

Continue Reading
Cryptocurrency Market Struggles as Bitcoin and Ethereum Drop

Updated Category News Views 183

Market Overview: Cryptocurrencies in Decline As the cryptocurrency market faces downward pressure, major cryptocurrencies are experiencing notable declines. Bitcoin, Ethereum, XRP, and Dogecoin have all dipped significantly due to various economic reactions. Recent data indicating stronger job growth has raised doubts about potential interest rate cuts by the Federal...

Continue Reading
Telephone and Data Systems Declares Q3 Dividends for 2025

Updated Category News Views 105

Telephone and Data Systems Announces Dividends for Q3 2025 Telephone and Data Systems, Inc. (NYSE: TDS) has recently declared its third quarter dividends for the year 2025, providing an update to shareholders regarding their investments. The company's commitment to rewarding its investors is exemplified through these dividend declarations for various share classes....

Continue Reading
Grant D. Ward Takes the Helm as CEO of Boston Mutual Life

Updated Category News Views 156

Grant D. Ward Joins as Chief Executive Officer Boston Mutual Life Insurance Company has exciting news as they appoint Grant D. Ward Sr., JD, as the new Chief Executive Officer and President, taking over the role effective January 1, 2026. This transition marks a new chapter for the company, with Ward succeeding Paul A. Quaranto Jr., who is set to retire at the end of...

Continue Reading
Havila Shipping ASA Reports Strong Q2 2025 Financial Growth

Updated Category News Views 175

Havila Shipping ASA's Exciting Financial Overview for Q2 2025 Havila Shipping ASA has reported its financial performance for the second quarter of 2025, showcasing remarkable growth in freight revenues. The company achieved a total of NOK 165.5 million in freight revenues, reflecting an increase of NOK 19.5 million compared to the same period last year. Additionally,...

Continue Reading